Drug Trial Radar · NCT07780669
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
624
Planned (sponsor's estimate)
Start
Aug 27, 2026
Primary completion
Jul 20, 2029
Study completion Mar 15, 2030
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Aug 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
GSK5784283Drug
GSK5784283 will be administered.
PlaceboDrug
Placebo will be administered.
Standard of careDrug
Standard of care will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized rate of moderate or severe COPD ExacerbationsTime frame: Up to Week 78
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Doral, Florida · Recruiting
GSK Investigational Site
Derby, Kansas · Recruiting
GSK Investigational Site
Lake Charles, Louisiana · Recruiting
GSK Investigational Site
Staten Island, New York · Recruiting
GSK Investigational Site
Humble, Texas · Recruiting
GSK Investigational Site
Huntsville, Texas · Recruiting
GSK Investigational Site
West Jordan, Utah · Recruiting
GSK Investigational Site
Fukuoka, Japan · Recruiting
GSK Investigational Site
Fukuoka, Japan · Recruiting
GSK Investigational Site
Ishikawa, Japan · Recruiting
GSK Investigational Site
Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.